Loading...

INKT MINK THERAPEUTICS INC Management Changes 8-K Filing

MNK

NKT

MINK THERAPEUTICS INC

(INKT)

2025 8-K

Financial Results Announced

Financial Results Report

Combination Trials Update

Management Changes

Board Resignation

Financial Results Announcement

Board Appointment

Financial Results Report

Equity Offerings

New Product Launches

Financial Statements

Financial Results

Financial Results

Director Appointment

Management Change

Financial Results

Annual Meeting of Stockholders

Stock Purchase Agreement

Financial Results Announcement

Financial Results Announcement

Delisting Notice

Agreement with Agenus Inc.

Financial Results Announcement

Resignation of Director

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

External Links:

On September 23, 2025, MiNK Therapeutics, Inc. appointed Dr. John Holcomb as a Class II director, granting him an option to purchase 4,174 shares of stock that vests over three years; the announcement was made public on September 29, 2025.

AI Assistant

MINK THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.